RoosterBio provides a standardized MSC product platform intended to simplify and accelerate human mesenchymal stem/stromal cell (hMSC) biomanufacturing and enable rapid clinical and commercial translation. The company aims to advance the cell-based bioeconomy by offering tools and products that streamline MSC development and manufacturing. RoosterBio raised a $21.5M Series B (including a $6.5M final tranche) to support its growth and global expansion initiatives. The financing is intended to help expand the company’s presence in worldwide markets and scale operations. Founded in 2013 and led by CEO Margot Connor, RoosterBio is based in Frederick, MD. At the time of the raise the company had 51 employees and planned to add 20 by the end of 2019 and approximately double headcount in 2020 to support global growth. RoosterBio Inc. is a biotech startup supplying human bone marrow-derived Mesenchymal Stem Cells (hBM-MSC) for tissue engineering research and stem cell-based product development. The company serves synthetic biology and regenerative medicine fields by providing hBM-MSC materials for research and product development. RoosterBio is led by Chief Executive Officer Dr. Jon Rowley and Chief Operating Officer Dr. Uplaksh Kumar. It initiated laboratory operations in October 2013 and is based in Frederick, MD. Financially, the company has raised over $250K in seed funding and is actively seeking additional funds via AngelList. No operating metrics (revenue/users) were disclosed in the article.

Total raised

$7M

Funding rounds

2

Latest round

Series B

Latest activity

Sep 2019